Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine versus etanercept for toxic epidermal necrolysis
IRCT20191020045169N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclosporine and etanercept in toxic epidermal necrolysis (TEN), sponsored by Shahid Beheshti University of Medical Sciences. Started Mar 2020; status: completed.
02
Drugs
cyclosporineetanercept
03
Conditions
toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on IRCT20191020045169N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191020045169N1.